|
[1]
|
COVID-19 Vaccine Technical Working Group. Technical vaccination recommendations for COVID-19 vaccines in China (First Edition). China CDC Wkly 2021;3(21):459 − 61. http://dx.doi.org/10.46234/ccdcw2021.083CrossRef
|
|
[2]
|
Liu FF, Zheng CJ, Wang LP, Geng MJ, Chen H, Zhou S, et al. Interpretation of the protocol for prevention and control of COVID-19 in China (Edition 8). China CDC Wkly 2021;3(25):527 − 30. http://dx.doi.org/10.46234/ccdcw2021.138CrossRef
|
|
[3]
|
National Health Commission of China. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8). http://www.gov.cn/zhengce/zhengceku/2021-04/15/content_5599795.htm. [2022-1-10]. (In Chinese). http://www.gov.cn/zhengce/zhengceku/2021-04/15/content_5599795.htm |
|
[4]
|
Al Kaabi N, Zhang Y, Xia S, Yang YK, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA 2021;326(1):35 − 45. http://dx.doi.org/10.1001/jama.2021.8565CrossRef
|
|
[5]
|
Palacios R, Batista AP, Albuquerque CSN, Patiño EG, Santos JDP, Conde MTRP, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3822780. [2021-4-11].https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3822780 |
|
[6]
|
Javier SV, Percy SB, Stefan EA, Manuel FN, Miguel MP, Lely S et al. BBIP-CorV vaccine effectiveness for preventing infection and death of health workers, Peru 2021 . https://repositorio.ins.gob.pe/xmlui/bitstream/handle/INS/1318/Efectividad%20de%20la.pdf. [2021-12-26]. (in Spanish).https://repositorio.ins.gob.pe/xmlui/bitstream/handle/INS/1318/Efectividad%20de%20la.pdf |
|
[7]
|
Wilder-Smith A, Mulholland K. Effectiveness of an inactivated SARS-CoV-2 vaccine. N Engl J Med 2021;385(10):946 − 8. http://dx.doi.org/10.1056/NEJMe2111165CrossRef
|
|
[8]
|
Ming Kang YY, Li Y, Sun LM, Deng AP. Effectiveness of inactivated COVID-19 vaccines against COVID-19 pneumonia and severe illness caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Guangdong, China. Lancet, 2021. preprint. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3895639.https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3895639 |
|
[9]
|
Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B. 1.617.2 (Delta) variant. N Engl J Med 2021;385(7):585 − 94. http://dx.doi.org/10.1056/NEJMoa2108891CrossRef
|